Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Larsucosterol - DURECT Corporation

Next Previous
X
Search
Drug Profile

Larsucosterol - DURECT Corporation

Alternative Names: 25HC3S; DUR-928; DUR-928 sodium - DURECT Corporation; DV-928; Larsucosterol sodium - DURECT Corporation

Latest Information Update: 03 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Virginia Commonwealth University
  • Developer DURECT Corporation
  • Class Anti-inflammatories; Antipsoriatics; Hepatoprotectants; Small molecules; Sterols; Urologics; Vascular disorder therapies
  • Mechanism of Action DNA methylation inhibitors; Inflammation mediator modulators; Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary sclerosing cholangitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alcoholic hepatitis
  • Phase I Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
  • Discontinued Acute kidney injury; Atopic dermatitis; Liver disorders; Plaque psoriasis; Primary sclerosing cholangitis; Psoriasis; Stroke

Most Recent Events

  • 25 Sep 2024 US FDA agrees to the key aspects of phase III registrational trial design in Alcoholic hepatitis
  • 13 Aug 2024 DURECT Corporation completes a Type B meeting with the US FDA to discuss the design of Phase III clinical trial of larsucosterol in Alcoholic hepatitis
  • 13 Aug 2024 DURECT plans a phase III registration trial for Alcoholic hepatitis in 2024 (IV, Injection)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top